% Expired Patents = 20.0

Forward Citations = 3

Loading Chart...

4 inventors (with patents filed for the assignee):

David Koos (3 out of 11 patents)

Thomas E Ichim (3 out of 54 patents)

Christine Victoria Ichim (2 out of 2 patents)

4. Richard Alexander Wells (1 out of 1 patent)

5 patents: Sort by Forward Citations

1. 11712474 - Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition (2023-08-01),

2. 11655474 - Suppression of pathological angiogenesis by inhibition of NR2F6 (2023-05-23),

3. 11090332 - Antigen specific mRNA cellular cancer vaccines (2021-08-17),

4. 10088485 - Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand (2018-10-02),

5. 9091696 - Modulation of NR2F6 and methods and uses thereof (2015-07-28),

Company Overview

Regen Biopharma, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of cancer and autoimmune disorders. The company utilizes cutting-edge research and technology to develop novel regenerative medicine products that have the potential to revolutionize patient care. With a strong commitment to scientific excellence and patient well-being, Regen Biopharma is dedicated to advancing the field of biopharmaceuticals and improving the lives of individuals around the world.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

5 Patents

#2 in La Mesa, CA

#12,070 in California

#51,620 in US

La Mesa, CA, United States of America

Regen Biopharma, Inc.

Forward Citations = 3

4 inventors:

David Koos (3 out of 11 patents)

Thomas E Ichim (3 out of 54 patents)

Christine Victoria Ichim (2 out of 2 patents)

4. Richard Alexander Wells (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Regen Biopharma, Inc.. Retrieved from https://idiyas.com/company/regen-biopharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]